Ticagrelor is more effective than clopidogrel at suppressing high platelet reactivity after transcatheter aortic valve implantation (TAVI). More than two thirds of patients undergoing TAVI have high platelet reactivity, and clopidogrel does not provide adequate platelet inhibition before or after the procedure in most patients. Over one third of patients who were initially responsive to clopidogrel became non-responsive in the first month after TAVI. In contrast, ticagrelor was effective at suppressing high platelet reactivity in over 90% of patients at 6 hours and 100% at 5 days after TAVI, and maintained this effect during the 3 months following the procedure, with no increase in bleeding